Supplementary Data

CRMP2 Hyperphosphorylation is Characteristic of Alzheimer’s Disease and not a Feature Common to Other Neurodegenerative Diseases

Ritchie Williamsona, Lidy van Aaltena, David M.A. Mannb, Bettina Plattc, Florian Plattnerd, Lynn Bedforde, John Meyere, David Howlettf, Alessia Usardig, Calum Sutherlanda and Adam R. Colea,

*Biomedical Research Institute, University of Dundee, Ninewells Hospital, Dundee, Scotland, UK
bNeurodegeneration and Mental Health Research Group, University of Manchester, Greater Manchester Neuroscience Centre, Hope Hospital, Salford, UK
cSchool of Medical Sciences, University of Aberdeen, Aberdeen, Scotland, UK
dInstitute of Neurology, University College London, London, UK
eSchool of Biomedical Sciences and School of Molecular Medical Sciences, University of Nottingham Medical School, Queen’s Medical Centre, Nottingham, UK
fGlaxoSmithKline, Harlow, Essex, UK
gInstitute of Psychiatry, Kings College London, London, UK

Accepted 13 July 2011
Supplementary Figure 1. Tau phosphorylation in some mouse models of AD. Cortical tissue from Tg2576 mice and age-matched controls were homogenized in 1% Triton X-100 lysis buffer, subjected to Western blot analysis and membranes probed with antibodies that recognize phosphorylated tau (AT8; upper panel) or total tau (tau-5; lower panel). The ratio of AT8:tau-5 in control and Tg2576 mouse cortex is presented as a graph. B) Same as A), except A/JPPPPSEN-1 versus control mouse cortex. C) Same as A), except A/JPPPPSEN/1x-tau triple-transgenic versus control mouse cortex. (average ± standard deviation; n.s. = not significant, * = p < 0.05 (Students t-test).

Supplementary Figure 2. CRMP2 phosphorylation is decreased in FTLD-tau diseases. Frontal cortex tissue lysates from 6 cases of human FTLD-tau associated with exon 10 + 16 mutation in MAPT and 18 with Pick body pathology, as well as 8 age-matched controls, were subjected to Western blot analysis. Membranes were probed with antibodies that specifically recognize CRMP2 when phosphorylated at Ser522 (first panel), Thr514/509 (second panel), total CRMP2 (third panel) and NSE as a loading control (fourth panel). Representative blots of control, FTLD (MAPT) and FTLD-tau (Pick’s Bodies) samples are shown.